MTIC (Standard)

[1]Ramalho MJ, et al. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156-163. |[2]Nagasawa HT, et al. The mechanism of alkylation of DNA by 5- (3-methyl-1-triazeno) imidazole-4-carboxamide (MIC), a metabolite of DIC (NSC-45388) . Non-involvement of diazomethane. Chem Biol Interact. 1974 Jun;8 (6) :403-13.|[3]Tsang LL, et al. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl- (triazen-1-yl) imidazole-4-carboxamide. Cancer Chemother Pharmacol. 1991;27 (5) :342-6.|[4]Beal DD, et al. Carcinogenicity of the antineoplastic agent, 5- (3,3-dimethyl-1-triazeno) -imidazole-4-carboxamide, and its metabolites in rats. J Natl Cancer Inst. 1975 Apr;54 (4) :951-7.